Moderna to expand BARDA agreement to support larger phase 3 program for Covid-19 vaccine
BARDA will extend an additional commitment of up to $472 million to support late stage clinical development including the expanded Phase 3 study of the Moderna’s mRNA vaccine candidate (mRNA-1273) against COVID-19.
Department of Biotechnology supports production scale-up of test kits from Mylab
The scale-up of Mylab’s pathodetect production is extension of DBT’s early support to support inventions from India in the fight against Covid. Mylab has a manufacturing capacity of 2,00,000 RT-PCR and 50,000 RNA tests.